ACTU (Actuate Therapeutics) EBITDA Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Actuate Therapeutics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Actuate Therapeutics's EBITDA for the three months ended in Dec. 2024 was $-6.44 Mil. Actuate Therapeutics's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Actuate Therapeutics's EBITDA margin for the quarter that ended in Dec. 2024 was 0.00%.

Actuate Therapeutics EBITDA Margin % Historical Data

The historical data trend for Actuate Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actuate Therapeutics EBITDA Margin % Chart

Actuate Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

EBITDA Margin %

Actuate Therapeutics Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EBITDA Margin %	Get a 7-Day Free Trial				-	-	-	-	-

Competitive Comparison of Actuate Therapeutics's EBITDA Margin %

For the Biotechnology subindustry, Actuate Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Actuate Therapeutics's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actuate Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Actuate Therapeutics's EBITDA Margin % falls into.

Save Embed

;

Save Embed

;

Actuate Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Actuate Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-27.267	/	0
	=	%

Actuate Therapeutics's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-6.441	/	0
	=	%

Actuate Therapeutics (NAS:ACTU) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Actuate Therapeutics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Actuate Therapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Actuate Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actuate Therapeutics Inc (NAS:ACTU) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1751 River Run, Suite 400, Fort Worth, TX, USA, 76107

Website

https://www.actuatetherapeutics.com

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.